PositoAI/ US/ NextCure, Inc.

NextCure, Inc.

NasdaqGS: NXTC · Healthcare

Positivity Index

#2,429 / 6,775

Global

#750 / 4,000

United States

Positivity Score

21,573

Rank→

Overview Go Deep Penta Pattern Funda News For this company Histo

PosiRed: no active red flags

NextCure, Inc. — Overview & Financial Snapshot

NextCure, Inc. (NasdaqGS: NXTC) is a Healthcare company, ranked #2,429 of 6,775 companies globally and #750 of 4,000 in United States on PositoAI, with a Positivity Score of 21,573. Its market capitalisation is ₹203.93 Cr ($21.61M), P/E ratio is -0.5 and P/B ratio is 1.78. It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

Top-ranked Healthcare companies

#3 Dogwood Therapeutics, Inc. 27,827 #8 Impact BioMedical Inc. 26,149 #13 Onconetix, Inc. 25,902 #15 Revelation Biosciences, Inc. 25,780 #18 Vyome Holdings, Inc. 25,696

— Nothing to show —

OpenAI is reading recent news...

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Baltimore, Maryland.

P/B Ratio 1.78

P/E Ratio -0.5

D/E Ratio 0.38

ROE -204.56%

Owes vs Owns ? 0.46× Low $0.46 owed for every $1 it owns · balance sheet Jun 2026

Dividend Yield 0.00%

Trailing EPS ₹-822.14$-8.71

Forward EPS ₹-556.43$-5.90

Beta 1.35

Market Cap ₹203.93 Cr$21.61M

What these numbers mean →

What does NextCure, Inc. do?

What is NextCure, Inc.'s P/E and P/B ratio?

NextCure, Inc. has a P/E ratio of -0.5 and a P/B ratio of 1.78.

What is NextCure, Inc.'s debt-to-equity ratio?

NextCure, Inc. has a debt-to-equity ratio of 0.38.

How much does NextCure, Inc. owe compared with what it owns?

NextCure, Inc. owes $0.46 for every $1 it owns (balance sheet Jun 2026), which is low.

What is NextCure, Inc.'s Positivity rank?

NextCure, Inc. is ranked #2,429 of 6,775 companies globally and #750 of 4,000 in United States on PositoAI, with a Positivity Score of 21,573.

Does NextCure, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for NextCure, Inc..

Where can I read the latest news about NextCure, Inc.?

Recent headlines about NextCure, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does NextCure, Inc. have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of NextCure, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

0 / 1000

🔒 Private — stored only in this browser, never sent to PositoAI. Clear anytime in Settings.